Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

Metastatic prostate cancer is also referred to as stage 4 or advanced prostate cancer. It's cancer that began in the prostate, a gland located under the bladder of people assigned male at birth, and ...

Metastasis-directed therapy added to ADT helps slow the progression of metastatic prostate cancer, a phase 2 trial finds. The addition of metastasis-directed therapy (MDT) to androgen deprivation ...

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on disease progression. Among patients with intermediate-risk prostate cancer, ...

Prostate cancer has four stages, which describe how advanced the cancer is and how far it has spread throughout your body. Knowing the stage of your cancer can help you and your healthcare team ...

Increased urinary urgency Frequent nighttime awakenings to urinate A slow or weak urinary flow Blood in the urine or semen As prostate cancer progresses and spreads to other areas of the body, it may ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...